K. Magnuson

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

J. O’Shea, A. Milici, B. Reitz, 2003, Science.

The specificity of JAK3 kinase inhibitors.

M. Munchhof, T. Harris, P. Changelian, 2008, Blood.

Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.

J. O’Shea, R. Wange, P. Changelian, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation

Massimo Gadina, Jerome Galon, John J. O'Shea, 2000, Molecular and Cellular Biology.

STAT Activation Syk nor Lck Is Required for IL-2-Mediated Syk Depends on Jak 3 ; However , Neither Interleukin-2 ( IL-2 ) Signaling : Activation of Hierarchy of Protein Tyrosine Kinases in

J. Galon, J. O’Shea, R. Geahlen, 2000 .

Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.

J. Roberts, J. O’Shea, R. Geahlen, 2001, Molecular cell.

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

M. Hines, M. Munchhof, P. Changelian, 2010, Journal of medicinal chemistry.

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer’s Disease

P. Aisen, M. Grundman, K. Marek, 2019, The Journal of Prevention of Alzheimer's Disease.

Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations

A. Ho, I. Braña, A. Gualberto, 2018 .